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Abstract
Osteoporosis is a condition characterized by low bone mass and increased bone fragility, putting
patients at risk of fractures, which are major causes of morbidity substantially in older people.
Osteoporosis is currently attributed to various endocrine, metabolic and mechanical factors.
However, emerging clinical and molecular evidence suggests that inflammation also exerts
significant influence on bone turnover, inducing osteoporosis. Numerous proinflammatory
cytokines have been implicated in the regulation of osteoblasts and osteoclasts, and a shift towards
an activated immune profile has been hypothesized as important risk factor. Chronic inflammation
and the immune system remodelling characteristic of ageing, as well as of other pathological
conditions commonly associated with osteoporosis, may be determinant pathogenetic factors. The
present article will review the current perspectives on the interaction between bone and immune
system in the elderly, providing an interpretation of osteoporosis in the light of inflamm-ageing.
Introduction
Osteoporosis is a relevant age related disorder, character-
ized by low bone mass and increased bone fragility
putting the patient at risk for fractures [1]. Currently oste-
oporosis is viewed as a heterogeneous condition which
can occur in any age of life and its etiology is attributed to
various endocrine, metabolic and mechanical factors
(abnormalities of parathyroid hormone and calcitonin
secretion, insufficient vitamin D and calcium intake, post-
menopausal hormonal condition, pregnancy, nutritional
disorders, immobility and consumption of drugs such as
cortisone, among others) [2]. Recently, growing under-
standing of the bone remodelling process suggests that
factors involved in inflammation are linked with those
critical for bone physiology and remodelling, supporting
the theory that inflammation significantly contributes to
the aetiopathogenesis of osteoporosis [3,4].
Is osteoporosis an inflammatory process?
Clinical observations reveal coincidence of systemic oste-
oporosis with period of systemic inflammation as well as
co-localization of regional osteoporosis with areas of
regional inflammation [2]. Different epidemiologic stud-
ies report an increase in the risk of developing osteoporo-
sis in various inflammatory conditions [5-8].
Immunological dysfunctions, autoimmune and chronic
inflammatory diseases [9], HIV infection [10], hyper-IgE
syndrome [11], rheumatoid arthritis [12], haematological
diseases, particularly myeloma [13], and inflammatory
bowel diseases [14], are associated with osteoporosis.
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Erosions seen in conditions such as gout, osteomyelitis,
rheumatoid arthritis, ankylosing spondylitis, and psori-
atic arthritis, are typically associated with inflammation in
the joints. Pro-osteoclastic cytokines, such as tumour
necrosis factor (TNF)-α and interleukin (IL)-6, are ele-
vated in these conditions and local cytokine profile is con-
sistent with the cytokines that modulate bone resorption
[15,16].
C-reactive protein (CRP) production in the liver is upreg-
ulated by IL-1, IL-6 and TNF-α, and is regarded as a sensi-
tive marker of systemic inflammation [17,18]. An
association between circulating high sensitive (hs)CRP
level and bone mineral density has been observed in sev-
eral immune and inflammatory diseases, as well as in
healthy individuals, suggesting a relationship between
subclinical systemic inflammation and osteoporosis [19].
Rheumatoid arthritis (RA) is a typical example of the link
between inflammation and osteoporosis. Bone loss in RA
occurs both in the joints and throughout the skeleton as a
result of the release of proteinases (metalloproteinases)
and proinflammatory cytokines (IL-1, TNF-α), which are
responsible for cartilage and bone destruction. As a result,
disease activity is an independent risk factor for oste-
oporosis in RA [20].
A temporal link between inflammation and osteoporosis
also emerges in conditions such as ageing, menopause,
pregnancy, transplantation and steroid administration.
While nutritional, mechanical and hormonal factors
clearly play a role in many of these situations, the con-
cordance of osteoporosis and inflammation is buttressed
by emerging molecular evidence of mediating immuno-
logical factors [2].
On the other hand, one intriguing aspect of immunose-
nescence is the increased production of pro-inflammatory
cytokines with age and a close link between age-related
systemic inflammatory process (inflamm-ageing)[21] and
osteoporosis is well documented [22].
A molecular scenario of immune regulated bone 
loss
Although osteoporosis is not typically considered an
immunological disorder, recent data have indicated over-
lapping pathways between bone biology and biology of
inflammation [23-25]. Certain pro-inflammatory
cytokines play potential critical roles both in the normal
bone remodelling process and in the pathogenesis of per-
imenopausal and late-life osteoporosis [26]. For example,
interleukin (IL)-6 promotes osteoclast differentiation and
activation [27]. This cytokine is involved in the pathogen-
esis of various metabolic bone diseases, including post-
menopausal osteoporosis, Paget's disease and
osteoporosis associated with heamtologic malignancies
[28]. IL-1 is another potent stimulator of bone resorption
[29] that has been linked to the accelerated bone loss seen
in idiopathic and postmenopausal osteoporosis [30].
TNF-α is implicated in tumour-induced bone resorption
and non-tumour-induced osteopenia [31]. Anti-TNF
drugs, currently used in the therapy of several immuno-
logical disorders, are also useful in preventing and/or
reversing systemic bone loss associated to the disease, as
they target both the bone and the inflammatory process
[20]. The production of IL-1, IL-6, and/or TNF-α by
peripheral blood monocytes has been positively corre-
lated with bone resorption or spinal bone loss in healthy
pre- and postmenopausal women [32].
The inflammatory mediator nitric oxide (NO) is also
involved in the pathogenesis of osteoporosis. The activa-
tion of the inducible NO synthesis (iNOS) pathway by
cytokines, such as IL-1 and TNF-α, inhibits osteoblast
function in vitro and stimulates osteoblast apoptosis [33].
The TNF-family molecule RANKL and its receptor RANK
(receptor activator of NFkB ligand) have been specifically
implicated in the bone loss in rheumatoid arthritis [34].
They are key regulators of bone remodelling and are
essential for the development and activation of osteo-
clasts. Intriguingly, RANKL/RANK interactions also regu-
late T cell/dendritic cell communication, dendritic cell
survival and lymphnode formation [35]. Calciotropic fac-
tors such as vitamin D3, PGE2, IL-1, IL-11, TNF-α and glu-
cocorticoid induce RANKL expression on osteoblasts [36].
RANKL binding to the RANK expressed on haematopoi-
etic progenitors activates a signal transduction cascade
that leads to osteoclast differentiation. Moreover, RANKL
stimulates bone resorbing activity in mature osteoclasts
via RANK. When RANK is activated, it sends signals into
the cells through tumor necrosis factor receptor-associ-
ated factors (TRAFs), mainly TRAF6. These RANK associ-
ated molecules, through downstream pathways such as
NF-kB, JNK/SAPK, p38 and Akt/PKB, regulate bone
resorption, activation, survival, and differentiation of
osteoclasts and dendritic cells.
Osteoprotegerin (OPG), also known as osteoclastogenesis
inhibitory factor, functions as a soluble decoy receptor to
RANKL and competes with RANK for RANKL binding.
TGFβ released from bone during active bone resorption
has been suggested as a feedback mechanism by upregu-
lating OPG level. Estrogen can enhance OPG production
on osteoblasts which is a possible explanation of post-
menopausal osteoporosis following estrogen withdrawal
[35]. Since the expression of RANKL/RANK can be con-
trolled by sex hormones, it is possible to speculate that
this system may control gender specific differences in
immunity and could be involved in the higher incidenceImmunity & Ageing 2005, 2:14 http://www.immunityageing.com/content/2/1/14
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of autoimmune diseases and osteoporosis in women.
RANK-L, RANK and OPG therefore configure interesting
molecular links between bone remodelling, immunity
and inflammation.
The emergence of osteoimmunology
There exists an intimate interplay between the bone and
the immune system which has been termed osteoimmu-
nology [3]. The activity of immune cells affects the bal-
ance of bone mineralization and resorption carried out by
the opposing actions of osteoblasts and osteoclasts [37].
Dendritic cells, specialized to present antigens, and osteo-
clasts, specialized to resorb bone, share the same bone
marrow precursors of the monocyte lineage and exhibit
parallel lifecycles, regulated by a variety of cytokines, tran-
scription factors and inflammatory mediators. Molecules
that regulate osteoclastogenesis are key factors in many
immunological functions. For example, TRAF6 functions
as a molecular bridge spanning adaptive immunity,
innate immunity and osteoimmunology [38]. TRAF6-
deficient mice lack osteoclasts and concomitantly have
defects in cytokine production and T cell stimulation [39].
Activated T cells affect bone physiology producing
cytokines that lead to RANKL expression on osteoblasts.
Moreover, activated T cells directly express and produce
RANKL that induces osteoclast formation and activation
through its specific receptor [28,35]. There are multiple
mechanisms and interactions by which cytokines regulate
bone resorption. IL-6 contributes to RANKL upregulation
in osteoblastic cells. IL-1 and TNF-α may not only pro-
mote osteoclast generation, but they also appear to stim-
ulate mature osteoclasts to perform more resorption
cycles through modulation of RANKL activity. IL-1 is fur-
ther involved in bone metabolism as an osteoblast activa-
tor: osteoblasts secrete RANKL which promotes survival
and differentiation of the osteoclast precursors to mature
osteoclasts through RANK. IL-1 and IL-6 also directly
enhance osteoclast activity by RANKL-independent mech-
anisms. They may directly extend the lifespan of the oste-
oclasts by inhibiting osteoclast apoptosis. Both TNF-α and
IL-1 inhibit collagen synthesis in osteoblasts and enhance
degradation of the extracellular matrix [18]. In inflamma-
tory or autoimmune disease states, activated T cells pro-
duce RANKL and pro-inflammatory cytokines, all of
which can induce RANKL expression in osteoblasts [40].
However, the constant activity of T cells fighting the uni-
verse of antigens to which we are exposed does not usually
cause extensive bone loss. Multiple T cell-derived
cytokines, such as IL-12 and IL-18, might be able to inter-
fere with RANK signalling and therefore with osteoclas-
togenesis and osteoclast functions. A crucial counter-
regulatory mechanism whereby activated T cells can
inhibit osteoclast development and activation is through
the action of the antiviral cytokine interferon (IFN)-γ.
Mechanistically, IFN-γ activates the ubiquitin-proteasome
pathway within the osteoclasts, resulting in the degrada-
tion of TRAF6 [38].
Ageing and osteoporosis: immunological links
Inflamm-ageing may, at least partially, be a common
mechanism for the development of lower bone mass and
other age-related disorders [41,42]. Senility is in fact nota-
ble for acceleration of diseases that are increasingly attrib-
uted to inflammation, such as atherosclerosis,
Alzheimer's disease and asthma [21,43,44]. Many
cytokines, including IL-6, TNF-α, IL-1, are elevated during
senescence and play direct roles in the pathogenesis of
these diseases [45]. All these cytokines are stimulators of
osteoclast activity as well. Associations between athero-
sclerosis and osteopenia have been well documented
[46,47]. These findings suggest a potential causal relation-
ship between systemic inflammation that is observed in
the elderly and the prevalence of generalized age-related
osteoporosis [2]. Moreover, the increased catabolic signal,
driven by inflammation also in the absence of clinically
diagnosable inflammatory diseases [44], could be able to
induce osteoblast apoptosis [48], as well as apoptosis of
muscle cells, leading to age-related osteoporosis and sar-
copenia respectively.
During ageing, under the influence of the lifelong expo-
sure to chronic antigenic load and oxidative stress, the
physiological counter-regulatory process which inhibits
bone resorption following T cell activation is likely
impaired. This would contribute, together with the age-
related systemic low-grade inflammation, to the increas-
ing incidence of osteoporosis during senescence.
Osteoporosis, as well as other age-related disorders, has a
strong genetic component and the rate extent of bone loss
during senescence varies widely between individuals. It is
tempting to postulate that this may be in part due to indi-
vidual differences in cytokine activity. In support of this
hypothesis it has been demonstrated that certain IL-6 pol-
ymorphisms are able to influence the risk of osteoporosis
in postmenopausal women [49]. Similarly, IL-1β and IL-1
receptor antagonist (IL-1Ra) gene polymorphisms are
associated with reduced bone mineral density and predis-
pose women to osteoporosis at the lumbar spine [50].
Moreover, also the sex hormonal decline which accompa-
nies ageing contributes to the pathogenesis of senile oste-
oporosis through immunologically mediated
mechanisms. It has been postulated that estrogens exert
their effect on bone not only by direct action per se, but
also by inhibiting IL-6 gene expression. A similar relation-
ship between androgen and IL-6 gene expression also
exists [51]. The decline in ovarian function is associatedImmunity & Ageing 2005, 2:14 http://www.immunityageing.com/content/2/1/14
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with decreased OPG production and spontaneous
increases in proinflammatory and pro-osteoclastic
cytokines such as IL-6, TNF-α, and IL-1 [32,52,53].
Osteoporosis within an evolutionary perspective
During evolution of multi-cellular organisms, the increas-
ing complexity of emerging systemic functions, such as
inflammation, may have led to a widening range of
demand for key minerals such as calcium and phosphate
and storage functions may have evolved to provide min-
eral reservoirs [2]. Moreover, calcium is an important
component of milk and its transport from mother to the
fetus and neonate is a vital process to preserve species.
Intriguingly, RANKL and RANK also play essential roles in
the formation of a lactating mammary gland in preg-
nancy. This could partly contribute to both the immune
remodelling and the accelerated bone loss during preg-
nancy and lactating [35]. Bone can thus be viewed as a
mobilizable reservoir of calcium and phosphate as salts.
Over time, the regulation of bone turnover was probably
optimized evolutionarily to address the combined meta-
bolic and structural demands of the host.
In this perspective osteoporosis may reflect a state of dise-
quilibrium between structural demand for calcium and
phosphate and their biologic demand during metaboli-
cally active states such as inflammation. Inflammation is
the leading force driving immunosenescence and the
chronic low-grade inflammatory state characteristic of
ageing represents the predisposing substrate on which
osteoporosis, as well as other age-related diseases, might
emerge [21,54].
The lack of evolutionary selective pressure post-reproduc-
tion may have further exacerbated this disequilibrium in
modern times and many biologic functions acquired dur-
ing evolution have become maladaptive. Presently, in
most developed countries, the human lifespan is greatly
increased, and many individuals are living into post-
reproductive senescence, an evolutionarily naive life
epoch. Obesity, diabetes, Alzheimer's disease and athero-
sclerosis are examples of diseases of modernity that are
attributable to modern living circumstances or that are
unmasked during senility, and also the emergence of oste-
oporosis as a modern disease may be an example of this
phenomenon [2,21,44].
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